Compare WTS & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WTS | CYTK |
|---|---|---|
| Founded | 1874 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.2B | 8.0B |
| IPO Year | 1986 | 2004 |
| Metric | WTS | CYTK |
|---|---|---|
| Price | $272.88 | $63.40 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 15 |
| Target Price | ★ $264.25 | $77.87 |
| AVG Volume (30 Days) | 178.1K | ★ 1.8M |
| Earning Date | 11-05-2025 | 11-05-2025 |
| Dividend Yield | ★ 0.76% | N/A |
| EPS Growth | ★ 16.19 | N/A |
| EPS | ★ 9.69 | N/A |
| Revenue | ★ $2,353,800,000.00 | $87,211,000.00 |
| Revenue This Year | $5.19 | $363.61 |
| Revenue Next Year | $4.22 | $64.33 |
| P/E Ratio | $28.10 | ★ N/A |
| Revenue Growth | 4.18 | ★ 2609.26 |
| 52 Week Low | $177.59 | $29.31 |
| 52 Week High | $287.89 | $69.33 |
| Indicator | WTS | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 49.70 | 49.91 |
| Support Level | $268.12 | $59.85 |
| Resistance Level | $280.09 | $69.33 |
| Average True Range (ATR) | 5.46 | 2.54 |
| MACD | 0.62 | -0.30 |
| Stochastic Oscillator | 59.02 | 38.29 |
Watts Water Technologies Inc is a U.S.-based company that provides safety, energy efficiency, and water conservation products. Its product portfolio includes residential and commercial flow control products, which are sold for plumbing and hot water applications; HVAC and gas products, including commercial boilers, water heaters, heating solutions, etc.; drainage and water reuse products, including drainage products and engineered rainwater-harvesting solutions; and water quality products, including point-of-use and point-of-entry water filtration, conditioning, and scale prevention systems. Its products are marketed through brands like Watts, Apex, Bradley, Nexa, and others. Geographically, the company derives its key revenue from the Americas, followed by Europe and the APMEA region.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.